AstraZeneca rejected another offer from Pfizer, saying the price was too low and ending all chances of creating the world's biggest drug maker. The $117 billion takeover offer was Pfizer's final offer and was rejected by the U.K. drug maker, as it failed to take into account experimental drugs in its pipeline and also the risks it presented to shareholders. The deal valued AstraZeneca at $92 per share, but the company said something closer to $98 per share would represent the true value of the company. "From our first meeting in January to our latest discussion yesterday, and in the numerous phone calls in between, Pfizer has failed to make a compelling strategic, business or value case. The Board is firm in its conviction as to the appropriate terms to recommend to shareholders," said AstraZeneca Chairman Leif Johansson. He added that the offer was a minor improvement upon Pfizer's third offer, but still continued to "fall short of the Board's view of value and has been rejected." The deal, which looks like it is dead, had split AstraZeneca shareholders, with many suggesting that the board was making a "gross miscalculation" in rejecting the offer. They also felt that the company should have engaged in constructive talks with Pfizer to reach an acceptable figure.
GMT 11:02 2018 Tuesday ,11 December
ASE opens trading on lower noteGMT 15:40 2018 Monday ,10 December
Amman stock market closes trading at JD4.4 millionGMT 19:10 2018 Wednesday ,05 December
Index at Palestine stock market drops by less than one pointGMT 17:58 2018 Sunday ,25 November
Amman stock market wraps up trading at JD2.6 millionGMT 14:24 2018 Thursday ,22 November
Russia’s stock market demonstrates record-breaking figures in 2018GMT 11:45 2018 Tuesday ,20 November
Tokyo stocks close lower as tech issues weigh, Nissan tumblesGMT 15:08 2018 Monday ,19 November
Amman stock market wraps up trading at JD6.1 millionGMT 15:51 2018 Sunday ,18 November
U.S. stocks post weekly losses amid tech shares routMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor